Eterna Therapeutics
ERNA
8 hedge funds and large institutions have $4.82M invested in Eterna Therapeutics in 2018 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 8 → 8 (0)
8% less capital invested
Capital invested by funds: $5.27M → $4.82M (-$448K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
+$145K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BA
1
Bard Associates
Chicago,
Illinois
| $1.33M | – | – | – |
|
|
NSIM
2
North Star Investment Management
Chicago,
Illinois
| $1.31M | – | – | – |
|
|
AIC
3
AWM Investment Company
New York
| $1.27M | +$145K | +2 | +12% |
|
|
EAM
4
Eagle Asset Management
St Petersburg,
Florida
| $319K | – | – | – |
|
5
Renaissance Technologies
New York
| $216K | – | – | – |
|
6
Geode Capital Management
Boston,
Massachusetts
| $94K | – | – | – |
|
7
Vanguard Group
Malvern,
Pennsylvania
| $94K | – | – | – |
|
|
CA
8
Callahan Advisors
Houston,
Texas
| $84K | – | – | – |
|
9
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $67K | – | – | – |
|
10
UBS Group
Zurich,
Switzerland
| $24K | – | – | – |
|
11
BlackRock
New York
| $13K | – | – | – |
|
|
KCPG
12
Kavar Capital Partners Group
Leawood,
Kansas
| $4K | – | – | – |
|
|
LTFS
13
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
ERNA Hedge Fund Activity: Q2 2018 in Review
8 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q2 2018, worth a combined $4.82M — down 8.5% from $5.27M a quarter earlier.
Fund positioning in ERNA was balanced in Q2 2018: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was AWM Investment Company, adding an estimated $145K.
- 8 institutional investors held Eterna Therapeutics (ERNA) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $4.82M of Eterna Therapeutics stock for Q2 2018, down 8.5% quarter-over-quarter.
- 0 funds opened new Eterna Therapeutics positions in Q2 2018 and 0 closed out.
- The largest Eterna Therapeutics buyer in Q2 2018 was AWM Investment Company, an estimated $145K added.
Based on aggregated 13F filings for Q2 2018.